Marc Beer is reigning the Chief Executive Officer of Renovia Inc., a company he co-founded for the express purpose researching, developing, and marketing female gender-specific products for their pelvic floor disorders. This female malady robs hundreds of millions of women of their ability to control the muscles of near their pelvic floor. The three main types of pelvic floor disorders are as follows: fecal incontinence, urinary incontinence, and pelvic organ prolapse. Women with fecal incontinence lacks the ability to control their bowel movement, while those with urinary incontinence lacks the ability to control their bladder. Women with pelvic organ prolapse have sunken uterus, bladder and bowel, which causes the vaginal canal to bulge. Among these three different types of pelvic floor disorders, urinary incontinence is by far the common type of pelvic floor disorders affecting over 250 million women across the globe. Women develop pelvic floor disorders as a consequence of giving birth, but this is not the only cause of pelvic floor disorders. Other causes include obesity, injury to the pelvic region, nerve damage, and surgery.
In order for Marc Beer to research, develop, and market female gender-specific products for their pelvic floor disorders, he needs substantial capital to pour into Renovia’s research and development programs. Thus, Marc Beer contacted three investors, the Missouri-based Ascension Ventures, the New York-based Perspective Advisors, and the Longwood Fund, and raised $42 million from them. The money raised will not only be used to research and development four new therapeutic and diagnostic products but also to develop an improved version of Leva, the company’s maiden product, which successfully gained the FDA’s approval in April of 2018.
Marc Beer is the quintessential CEO in that he possesses well over 25 years of experience in the area of developing and commercializing biotechnology, devices, pharmaceuticals, and diagnostics. He received his college degree from Miami University in Ohio. Apart from co-founding Renovia, Marc Beer has founded a good many number of other biotech companies, such as ViaCell, Minerva Neurosciences Inc., and Good Start Genetics, Inc. Marc Beer founded ViaCell in April 2000, a biotech company which specializes in the area of not only collecting but preserving and developing umbilical cord blood stem cells as well. Marc Beer so exceptionally managed and led ViaCell that the biotech went public in 2005. Marc Beer has also founded Good Start Genetics, Inc. and has served as its chairman of the compensation committee and chairman of the board of directors, as well as Minerva Neurosciences Inc. and served as its chairman of the board, chairman of the compensation committee, and a member of the company’s audit committee. Learn more: https://ideamensch.com/marc-beer/